How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

SN

LSE:Synairgen
Get a brief AI stock analysisSaves ~ 15 minutes of your time

SN

Synairgen PLCLSE Synairgen Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XLON - London Stock Exchange

FAIR VALUE

Is SNG undervalued compared to its fair value?

The fair value of SNG stock is hidden GBX. Relative to the market price of 4.645 GBX Synairgen PLC is hidden.

Synairgen Plc is a holding company, which engages in the provision of respiratory drug discovery and development. The Company’s primary focus is developing SNG001 (inhaled interferon beta) for the treatment of severe vir...[More about valuation]

Synairgen PLC Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.012 $B

Price:

4.645 GBX

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.024

FINANCIALS

Synairgen PLC financial for reporting period

Income Statement


Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0055 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0047 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

Balance Sheet

0.019 B
0.016 B

Financial Position Analysis

Assets

0.019 B
Current Assets
0.019 B
Total non-current assets
0.0001 B

Total current liabilities
0.0027 B
Total non-current liabilities

Cash Flow Statement

-0.0054 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0053 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Synairgen PLC fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is SNG attractive for investment based on fundamental analysis?

SNG stock rating is hidden. Synairgen PLC is a hidden by Eyestock methodology.

Get SNG Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

Debt / Equity ratio:

ROE:

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

SNG.L analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for SNG.L to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Synairgen PLC competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

Synairgen PLC dividends

SNG.L dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About SNG.L stock

About the company Synairgen PLC

Market cap $B

0.012

Dividend yield

Shares outstanding

201.375 B

Synairgen Plc is a holding company, which engages in the provision of respiratory drug discovery and development. The Company’s primary focus is developing SNG001 (inhaled interferon beta) for the treatment of severe viral lung infections, including COVID-19 as potentially the first host-targeted, antiviral treatment delivered directly into the lungs. The firm is also engaged in the drug discovery and development of therapies for respiratory diseases, particularly in areas, including severe asthma and chronic obstructive pulmonary disease (COPD).

SNG.L profile

  • Ticker

    SNG.L

  • Country

    Great Britain

  • Exchange

    XLON - London Stock Exchange

  • Report currency

    GBP - British pound

  • IPO date

    26 October 2004

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    24

  • City

    SOUTHAMPTON

  • Address

    Mailpoint 810, Level F, South Block, Southampton General Hospital

  • Cusip

    G86488106